Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma

J Invest Dermatol. 2013 Jan;133(1):274-6. doi: 10.1038/jid.2012.268. Epub 2012 Aug 16.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • 9,10-Dimethyl-1,2-benzanthracene / toxicity
  • Administration, Topical
  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Carcinogens / toxicity
  • Carcinoma, Squamous Cell / chemically induced
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / pathology
  • Cell Line
  • Cell Proliferation / drug effects
  • Fluorouracil / therapeutic use*
  • Humans
  • Imidazoles / adverse effects
  • Indoles / adverse effects
  • Melanoma / drug therapy*
  • Mice
  • Oximes / adverse effects
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
  • Skin Neoplasms / chemically induced
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Sulfonamides / adverse effects
  • Tetradecanoylphorbol Acetate / toxicity
  • Vemurafenib

Substances

  • Antineoplastic Agents
  • Carcinogens
  • Imidazoles
  • Indoles
  • Oximes
  • PLX 4720
  • Sulfonamides
  • Vemurafenib
  • 9,10-Dimethyl-1,2-benzanthracene
  • Braf protein, mouse
  • Proto-Oncogene Proteins B-raf
  • Tetradecanoylphorbol Acetate
  • dabrafenib
  • Fluorouracil